RxDoctor Payments Data

Pamela Anderson

Family · Wauwatosa, WINPI 1558929091

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 14 payments — averaging $73.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$289
  • E.r. Squibb & Sons, L.L.C.$216
  • Boehringer Ingelheim$203
  • AstraZeneca$125
  • Boston Scientific$112
  • Novartis$26
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$1,024100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,024 in reported general payments places this provider in the 80th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$9,093
Medicare patients
105
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$52,032
EntrestoSacubitril/Valsartan26$30,574
XareltoRivaroxaban24$24,223
Metoprolol Succinate76$725
Atorvastatin Calcium60$527
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$438
Furosemide69$434
Nitroglycerin15$411
Carvedilol38$319
Lisinopril38$284
ClopidogrelClopidogrel Bisulfate26$170
Losartan Potassium24$162
Rosuvastatin Calcium13$146
Amlodipine Besylate25$112
Metoprolol Tartrate15$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$26$30,57426 claims
Johnson & JohnsonXarelto$289$24,22324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,273 family providers in Wisconsin.

Other family in Wauwatosa

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →